Denali Therapeutics (DNLI) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 113.4% versus a gain of 19.3%. Over five years, URGN leads with a +117.3% price change compared with -59.0% for DNLI. Denali Therapeutics is the larger company by market cap ($2.98 billion vs $1.81 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | URGN |
|---|---|---|
| Share price | $18.67 | $36.98 |
| Market cap | $2.98B | $1.81B |
| 1-day change | -2.56% | -9.14% |
| YTD return | +13.08% | +57.90% |
| 1-year return | +19.30% | +113.39% |
| 5-year return | -59.02% | +117.27% |
| Forward P/E | — | 13.23 |
| EPS (TTM) | $-2.84 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-512.54M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $27.30 | $50.81 |
| 52-week low | $13.75 | $15.86 |
| Distance from 52-week high | -31.61% | -27.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.14% | +62.25% |
| Average volume | 1.62M | 849.01K |
| Shares outstanding | 159.85M | 48.88M |
| Employees | 503 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed DNLI by 94.1 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
DNLI vs URGN FAQ
Which is bigger, Denali Therapeutics or UroGen Pharma?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.98B compared with $1.81B for UroGen Pharma (URGN).
Which stock has performed better over the past year, DNLI or URGN?
URGN returned +113.39% over the past 12 months, compared with +19.30% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and UroGen Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for UroGen Pharma.